September is Arrhythmia Awareness month, providing thirty days for us to draw attention to the cause that brought the BioSig team together. In an attempt to increase awareness, I would like to take this opportunity to further educate the BioSig community about common cardiac arrhythmias. My hope is that this information will reach more folks than just a single individual who reads this blog post, as there is great power in communication.
The average person in the United States may not be aware of the prevalence and severity of cardiac arrhythmias and their associated diseases. Arrhythmia is the name for the overarching disease that encompasses both Atrial Fibrillation (AFib) and Ventricular Tachycardia (VT). AFib is a condition classified by an irregular heartbeat that can cause stroke, blood clots, heart failure, and other heart-related deficiencies if not treated correctly or within a timely manner. Comparably, VT occurs when abnormal electrical signals cause the ventricles of the heart to beat at a different rate than the rest of the heart, resulting in reduced blood flow due to the inefficient filling of the heart chambers. These diseases sometimes fall under the radar and become unidentifiable in comparison to more widespread heart diseases. Although people may not be as familiar with the arrhythmias, it affects a large portion of the U.S. and global population each year and is expected to affect more Americans in the years to come.
Arrhythmias in general hospitalize more than 850,000 Americans* each year. Between the two conditions, AFib is the most prevalent, affecting 33.5 Million people worldwide*, although VT is the more serious diagnosis, resulting in an estimated rate of approximately 300,000 deaths per year*. According to Cleveland Clinic, by 2050, 8 million Americans are expected to be affected by AFib. AFib generally affects adults between the ages of 65 and 85, which accounts for 70% of the overall population of those diagnosed with AFib. Men have higher rates of AFib than women across each age group; however, women with AFib are at greatest risk of stroke and death than men with AFib.
By illuminating these statistics, we draw attention to arrhythmias, such as AFib and VT, providing an introduction to where BioSig fits into this sector of healthcare. With our recently FDA-approved, innovative Pure EP™ System, we hope to offer a viable treatment option that physicians can implement to further prevent these diseases. If the content in this post sparks any questions you might have, or would like to speak to our Investor Relations team, please get in touch with us at email@example.com.
Chairman & CEO
BioSig Technologies, Inc.
* Sources: Healthline; Worldwide Epidemiology of Atrial Fibrillation in the journal Circulation, 2013; CDC Fact Sheet on Atrial Fibrillation; American Heart Association; Ventricular Tachycardia in Medscape, December 2017